Trichomonosis, a Common Curable STI, and Prostate Carcinogenesis—A Proposed Molecular Mechanism

article has not abstract

Vyšlo v časopise: Trichomonosis, a Common Curable STI, and Prostate Carcinogenesis—A Proposed Molecular Mechanism. PLoS Pathog 8(8): e32767. doi:10.1371/journal.ppat.1002801
Kategorie: Pearls
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002801

Souhrn

article has not abstract

Zdroje

1. Hobbs MM, Sena AC, Swygard H, Schwebke JR. (2008) Trichomonas vaginalis and trichomoniasis. In: Sexually transmitted diseases. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, Cohen MS, Watts DH, editors. Sexually transmitted diseases. New York: McGraw-Hill Medical. 771–793.

2. SiegelR, NaishadhamD, JemalA (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.

3. MittereggerD, AberleSW, MakristathisA, WalochnikJ, BrozekW, et al. (2012) High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue. Med Microbiol Immunol 201: 113–116.

4. GardnerWA, CulbersonDE, BennettBD (1986) Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med 110: 430–432.

5. StarkJR, JudsonG, AldereteJF, MundodiV, KucknoorA, et al. (2009) Trichomonas vaginalis infection and prostate cancer incidence and mortality: a prospective study in the physician's health study. J Natl Cancer Inst 101: 1–6.

6. SutcliffeS, GiovannucciE, AldereteJF, ChangTH, Gaydos, et al. (2006) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 939–945.

7. SutcliffeS, AldereteJF, TillC, GoodmanPJ, HsingAW, et al. (2009) Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Intl J Cancer 124: 2082–2087.

8. De MarzoAM, PlatzEA, SutcliffeS, XuJ, GronbergH, et al. (2007) Inflammation in prostate carcinogenesis. Nature Rev Cancer 7: 256–269.

9. DianaF, Di BernardoJ, SgarraR, TessariMA, RustighiA, et al. (2005) Differential HMGA expression and post-translational modifications in prostate tumor cells. Int J Oncol 26: 515–520.

10. ShahN, PangB, YeohKG, ThornS, ChenCS, et al. (2008) Potential roles for the PIM1 kinase in human cancer—a molecular and therapeutic appraisal. Eur J Cancer 44: 2144–2151.

11. ValdmanA, FangX, PangST, EkmanP, EgevadL (2004) PIM1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60: 367–371.

12. WangJ, KimJ, FrancoOE, HaywardSW, WillsML, et al. (2010) Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29: 2477–2487.

13. KucknoorAS, MundodiV, AldereteJF (2007) The proteins secreted by Trichomonas vaginalis and vaginal epithelial cell response to secreted and episomally expressed AP65. Cell Microbiol 9: 2586–2597.

14. RyuJS, KangJH, JungSY, ShinMH, KimJM, et al. (2004) Production of interleukin-8 by human neutrophils stimulated with Trichomonas vaginalis. Infect Immun 72: 1326–1332.

15. DhanasekaranSM, BarretteTR, GhoshD, ShahR, VaramballyS, et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826.

16. HanIH, ParkSJ, AhnMH, RyuJS (2012) Involvement of mast cells in inflammation induced by Trichomonas vaginalis via crosstalk with vaginal epithelial cells. Parasite Immunol 34: 8–14.

17. AzevedoA, CunhaV, TeixeiraAL, MedeirosR (2011) IL-6/IL6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2: 384–396.

18. StarkJR, LiH, KraftP, GiovannucciEL, StampferM, et al. (2009a) Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 124: 2683–2689.

19. MagnusonNS, WangZ, DingG, ReevesR (2010) Why target PIM1 for cancer diagnosis and treatment? Future Oncol 6: 1461–1478.

20. RohM, FrancoOE, HaywardSW, van der MeerR, AbdulkadirSA (2008) A role for polyploidy in the tumorigenicity of PIM1-expressing human prostate and mammary epithelial cells. PLoS ONE 3: e2572 doi:10.1371/journal.pone.0002572.

21. SansoneP, BrombergJ (2012) Targeting the interleukin-6/jak/stat pathway in human malignancies. J Clin Oncol 30: 1005–1014.

22. ReevesR, BeckerbauerL (2001) HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519: 13–29.

23. ZhangY, WangZ, LiX, MagnusonNS (2008) Pim-1 kinase-dependent inhibition of c-MYC degradation. Oncogene 27: 4809–4819.

24. HillionJ, DharaS, SumterTF, MukherjeeM, Di CelloF, et al. (2008) The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an Achilles heel for hematopoietic malignancies? Cancer Res 68: 10121–10127.

25. TesfayeA, Di CelloF, HillionJ, RonnettBM, ElbahloulO, et al. (2007) The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 67: 3998–4004.

26. CowanMJ, CollT, ShelhamerJH (2006) Polyamine-mediated reduction in human airway epithelial migration in response to wounding is PGE2 dependent through decreases in COX-2 and cPLA2 protein levels. J Appl Physiol 101: 1127–1135.

27. GarciaA, BenchimolM, AldereteJF (2005) Trichomonas vaginalis polyamine metabolism is linked to host cell adherence and cytotoxicity. Infect Immun 73: 2602–2610.

28. HuXF, LiJ, VandervalkS, WangZ, MagnusonNS, et al. (2009) PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119: 362–375.